



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an Envelope addressed to: Mail Stop Disclosure Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on:

Date:

9/13/06

By:

Winsome A. St. Rose

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Martin Dugas, et al.l.,

SERIAL NO.: 10/575,704

PCT FILING DATE: NOVEMBER 4, 2004

FOR: **METHOD FOR DISTINGUISHING
AML SUBTYPES WITH DIFFERENT
GENE DOSAGES**

)

) EXAMINER: N/A

) ART UNIT: N/A

) Confirmation No. 2362

) DOCKET NO. 22337-US

INFORMATION DISCLOSURE STATEMENT

Mail Stop Disclosure.
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicant submits herewith a Form-1449, in compliance with the duty of disclosure requirements of 37 C.F.R. §1.56, 1.97 and 1.98, listing accompanying documents that may be considered material to the examination of this application. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits, whichever event occurs last. No certification or fee is therefore required under 37 C.F.R. § 1.97(b). However, should the Commissioner determine that fees are due in order for the Information Disclosure Statement to be considered at this stage, the Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to Deposit Account No. 50-0812.

Applicants wish to provide the USPTO with electronic copies of WO 03/039433A2 and WO 03/083140 A2, which individually, exceeds 2,900 pages.

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested.

Respectfully submitted,

Date:

9/12/06

Robert W. Mann
Robert W. Mann
Reg. No. 48,555

Correspondence Address:

Roche Molecular Systems, Inc
1145 Atlantic Avenue
Alameda, CA 94501
Tele: (510) 814-2800
Fax: (510) 814-2973


LIST OF INFORMATION CITED BY APPLICANT

(Use several sheets if necessary)

Applicants: Martin Dugas, et al.

Int'l Filing Date: November 4, 2004

Group: Unassigned

**U.S. PATENT DOCUMENTS**

* EXAMINER INITIAL		DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	1	5,210,015	05/11/93	Gelfand, et al	435	6	08/06/90
	2	5,445,934	08/29/95	Fodor, et al	435	6	09/30/92
	3	5,487,972	01/30/96	Gelfand, et al	435	6	01/05/93
	4	5,700,637	12/23/97	E. Southern	435	6	04/19/94
	5	5,744,305	04/28/98	Fodor, et al	435	6	06/06/95
	6	5,804,375	09/08/98	Gelfand, et al	435	6	04/25/95
	7	5,945,334	08/31/99	Besemer, et al	435	287.2	06/07/95
	8	6,174,670 B1	01/16/01	Wittwer, et al	435	6	06/04/97
	9	2003/0138793 A1	07/24/03	Su, et al	435	6	06/10/02

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	10	0 373 203 B1	08/31/94	EP			
	11	0 619 321 B1	01/07/90	EP			
	12	1 043 676 A1	10/11/00	EP			
	13	WO 92/02638	02/20/92	PCT			
	14	WO 03/039443 A2	05/15/03	PCT			
	15	WO 03/083140 A2	10/09/03	PCT			
	16	WO 2005/043167 A3	05/12/05	PCT			
	17	EP2004/012469 Search Report	07/13/05	PCT			

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	18	Alizadeh, A., et al., 1999, "The Lymphochip: A Specialized cDNA Microarray for the Genomic-scale Analysis of Gene Expression in Normal and Malignant Lymphocytes", Cold Springs Harbor Symposium on Quantitative Biology, Volume LXIV, Cold Springs Harbor Laboratory Press, pp 71-78
	19	Brown, M., et al, 2000, "Knowledge-based analysis of microarray gene expression data by using support vector machines, PNAS, 97(1):262-267
	20	Chen, J-S., et al., 2001, "Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia", Blood, 97(7):2115-2120
	21	Dugas, M., et al., 2001, "A comprehensive leukemia database: integration of cytogenetics, molecular genetics and microarray data with clinical information, cytomorphology and immunophenotyping", Leukemia, 15:1805-1810
	22	Dugas, M., et al., 2002, "Impact of Integrating Clinical and Genetic Information", In Silico Biology, 2:383-391
	23	Furey, T., et al., 2000, "Support vector machine classification and validation of cancer tissue samples using microarray expression data", Bioinformatics, 16(10):906-914

	24	Golub, T., et al, 1999, "Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring", <i>Science</i> , 286:531-537
	25	Haferlach, T., et al., "Abstract: The Diagnosis of 14 Specific Subtypes of Leukemia Is Possible Based on Gene Expression Profiles: A Study on 263 Patients with AML, ALL, CML, or CLL", <i>Blood</i> , 100, Abstract 523
	26	Harlow, E., et al, 1988, "Antibodies A Laboratory Manual", <i>Cold Spring Harbor Laboratory</i>
	27	Koehler, G., et al., 1975, "Continuous cultures of fused cells secreting antibody of predefined specificity", <i>Nature</i> , 256:495-497
	28	Kohlmann, A., et al., 2002, "Abstract: A Simplified and Partially Automated target Preparation Method for Gene Expression Profiling", <i>Blood</i> , 100, Abstract 4287
	29	Kohlmann, A., et al., 2003, "Molecular Characterization of Acute Leukemias by Use of Microarray Technology", <i>Genes, Chromosomes & Cancer</i> , 37:396-405
	30	Liu, G., et al., 2003, "NetAffx: Affymetrix probesets and annotations", <i>Nucleic Acids Research</i> , 31(1):82-86
	31	Qian, Z., et al., 2002, "Expression Profiling of CD34+ Hematopoietic Progenitors Reveals Distinct Subtypes of Therapy-Related Acute Myeloid Leukemia", <i>Blood</i> , 100, Abstract 1206
	32	Qian, Z., et al., 2002, "Expression profiling of CD34+ hematopoietic stem/progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia", <i>PNAS</i> , 99(23):14925-14930
	33	Ritter, M., et al., 2002, "Differentially Regulated Signaling Pathways in AML with Monosomy 7 and 7q-", <i>Blood</i> , 100, Abstract 4309
	34	Sambrook, J., et al., 1989, "Molecular Cloning A Laboratory Manual Second Edition", <i>Cold Spring harbor Laboratory Press</i> ,
	35	Schoch, C., et al., 2001, "Abstract: Specific abnormalities on the genomic level result in a distinct gene expression pattern detected by oligonucleotide microarrays: An analysis of 25 patients with AML M2/t (8;21), AML M3/M3v/t (15;17), and AML M4eo/inv(16), <i>Blood</i> , 98: pp 92a – 93a
	36	Schoch, C., et al., 2002, "Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles", <i>PNAS</i> , 99(15):10008-10013
	37	Storey, J., et al., 2003, "Statistical significance for genomewide studies," <i>PNAS</i> , 100(16):9440-9445
	38	Vey, Norbert, et al., 2002, "Abstract: Gene Expression Profiling of Acute Myeloid Leukemias with Normal Karyotype," <i>Blood</i> , 100: Abstract No. 2949
	39	Virtaneva, K., et al., 2001, "Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics." <i>PNAS</i> , 98(3):1124-1129
EXAMINER		DATE CONSIDERED
*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		